PT - JOURNAL ARTICLE AU - Masirika, Leandre Murhula AU - Nieuwenhuijse, David F. AU - Ndishimye, Pacifique AU - Udahemuka, Jean Claude AU - Steeven, Bilembo Kitwanda AU - Gisèle, Nzigire Barhatwira AU - Musabyimana, Jean Pierre AU - Daniel, Baganda Ntahuma AU - Kiluba wa Kiluba, Théophile AU - Mweshi, Franklin Kumbana AU - Ngabo, Polepole AU - Tambala, Theophile AU - Divin, Mazambi Mambo AU - Chance, Bahati Mutalemba AU - Mambo, Léandre Mutimbwa AU - Schuele, Leonard AU - Mbiribindi, Justin Bengehya AU - Martinez, Gustavo Sganzerla AU - Kelvin, David J AU - Maboko, Gaston Lubambo AU - Oude Munnink, Bas B. AU - Lang, Trudie AU - Aarestrup, Frank M. AU - Gortazar, Christian AU - Koopmans, Marion AU - Siangoli, Freddy Belesi TI - Mapping the distribution and describing the first cases from an ongoing outbreak of a New Strain of mpox in South Kivu, Eastern Democratic Republic of Congo between September 2023 to April 2024 AID - 10.1101/2024.05.10.24307057 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.10.24307057 4099 - http://medrxiv.org/content/early/2024/05/10/2024.05.10.24307057.short 4100 - http://medrxiv.org/content/early/2024/05/10/2024.05.10.24307057.full AB - Background In September 2023, an outbreak of mpox was reported in the eastern part, South Kivu Province, of Democratic Republic of the Congo. This paper aims to provide a summary from several ongoing and completed studies to share initial insights into the time trend and spatial distribution, the links we have observed between level of mpox cases with population density and the presence of professional sex workers (PSW) in bars within affected heath areas of Kamituga health zone. We also seek to share our initial observations on the novel characteristics of this new and emergent strain.Methods Consenting patients admitted with mpox-like symptoms to the Kamituga hospital were recruited to an observational cohort study to understand the clinical characteristics and household perceptions and treatment seeking behaviours. We mapped the demographic and clinical characteristics of all individuals between September 2023 and April 2024.Findings 371 (suspected) mpox cases were admitted to the Kamituga hospital. There were slightly more female than male cases (192/371 [52%] versus 179/371, [48%], and cases were reported from 15 health areas. The majority of cases were reported in Mero (115/371 [31%]), followed by Kimbangu (65/371[18%]), Kabukungu (63/371[17%]), Asuku (47/371 [13%]), Soluluyu (19/371 [5,12%]), Katunga (17/371 [4,58%]), Kalingi, Poudriere (12/371 [3,23%]) respectively, and Poly Afia (7/371 [1,89%]). During this period, 4 deaths occurred and 4 out of 8 women who were pregnant had fetal loss . Three healthcare workers acquired infection when caring for patients. In depth case ascertainment showed that 88,4 % of patients reported recent visits to bars for (professional) sexual interactions as a likely source of infection. Our findings suggest that the epidemic in South Kivu is driven by transmission in a network of professional sex workers, working in bars. The continued spread of the mpox virus in Kamituga health zone and other health zones of South -Kivu points at a critical need for cross border surveillance, and the potential for rapid vaccination of sex workers as potential intervention.Interpretation These data suggest that the rapid transmission of mpox virus is related to interactions with professional sex workers (PSW) in bars within densely populated health areas. The expanding number of cases and the recent spillover to 16 other nearby health zones of South -Kivu including a health district bordering Rwanda and Burundi stresses the need for cross border surveillance. In addition, enhanced response action is needed, including vaccination health education programmes to limit further escalation and stop this outbreak.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Kamituga hospital local researchers and an MRC grant has been awarded to the team for the ongoing long-term follow up and disease characterisation studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical clearance to conduct these studies was obtained from the Ethical Review Committee of the Catholic University of Bukavu (Number UCB/CIES/NC/022/2023 and University of Oxford : OxTREC Reference : 517-24).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yesclinical data is available upon the reasonable request to the correspoding auther